Search results
Results From The WOW.Com Content Network
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd [3] with production facilities in nine countries and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28% of its shares and a majority (77%) of its voting shares.
The Novo Nordisk Foundation is an international enterprise foundation focusing on medical treatment and research. In 2023, the foundation had a net worth of $167 billion (1,114 billion DKK), [2] [3] making it the wealthiest charitable foundation in the world.
The overall purpose of Novo Holdings A/S is to hold the position as the controlling majority shareholder of the Novo Group companies (Novo Nordisk A/S and Novozymes A/S), aiming at making a positive impact on health, science and society by generating long-term returns on the assets of the Novo Nordisk Foundation. [12]
In 1998 a team of researchers at Novo Nordisk led by the scientist Lotte Bjerre Knudsen developed liraglutide, a glucagon-like peptide-1 receptor agonist that could be used to treat diabetes. [ 45 ] Clinical trials and early approvals for diabetes
Lars Fruergaard Jørgensen (born 29 November 1966) [1] is a Danish businessman, the Chief Executive of Novo Nordisk since January 2017 and Chairman of the European Federation of Pharmaceutical Industries and Associations. He was named as the Financial Times Person of the Year in December 2023.
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in discovering and developing treatment for serious chronic disease, like diabetes and obesity.
Knudsen began work as a scientist at the pharmaceutical company Novo Nordisk in Denmark in 1989. [2] As of December 2015, she was being referred to as Scientific Vice President for Global Research at Novo-Nordisk. [4] She served as an adjunct faculty member at Aarhus University from 2015-2020, as a professor in translational medicine. [2]Knudsen has been employed as a Chief Scientific Advisor ...
Our history spans a century and it all began with two small Danish companies, Nordisk Insulinlaboratorium and Novo Terapeutisk Laboratorium. After hearing of the discovery of insulin in 1921, Danish Nobel laureate August Krogh and his wife Marie, a doctor living with diabetes, were intrigued.
Read about our history of innovation and philanthrophy. The Novo Nordisk Way describes the values and behaviors that guide everything we do. It is rooted in the principles and vision of our founders who set out on an ambitious journey to drive change for patients with diabetes in 1923.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases.